In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II (SGLT2) Inhibitor, in Animals and Humans
نویسندگان
چکیده
Department of Pharmaceutical Candidate OptimizationMetabolism and Pharmacokinetics (M.O.), Department of Pharmaceutical Candidate OptimizationDevelopment Biotransformation (M.Y., M.Z., W.L., W.G.H.), SV Life Sciences LLC, Foster City, CA (A.K), Duck Flats Pharma, Elbridge, NY (B.Kop.), Department of Global Marketing (B.Kom.), Department of Discovery Medicine and Clinical Pharmacology (S.K.), Department of Pharmaceutical Candidate OptimizationBioanalytical Research (L.D.), Department of Metabolic Diseases Biology (J.W.), and Department of Metabolic Diseases Chemistry (W.W., W.M., B.A.E.), BristolMyers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA DMD Fast Forward. Published on December 8, 2009 as doi:10.1124/dmd.109.029165
منابع مشابه
In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
(2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2H-pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes. The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological...
متن کاملDapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
OBJECTIVE The inhibition of gut and renal sodium-glucose cotransporters (SGLTs) has been proposed as a novel therapeutic approach to the treatment of diabetes. We have identified dapagliflozin as a potent and selective inhibitor of the renal sodium-glucose cotransporter SGLT2 in vitro and characterized its in vitro and in vivo pharmacology. RESEARCH DESIGN AND METHODS Cell-based assays measur...
متن کاملSafety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new glucose-lowering therapy for T2DM with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. They have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. There is some concern about the safety of using SGLT2 inhibitors in Muslim type 2 diabete...
متن کاملEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
Although antidiabetic agents have been developed to target one or more of the core defects of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition of the sodium-glucose cotransporter 2 (SGLT2) induces glycosuria, reduces glucose toxicity and improves insulin sensitivity and β-cell function. As the mechanism of action of SGLT2 inhibitors is different from othe...
متن کاملSodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
Pharmacological inhibition of the proximal tubular sodium-glucose linked cotransporter-2 (SGLT2) leads to glycosuria in both diabetic and non-diabetic settings. As a consequence of their ability to modulate tubuloglomerular feedback, SGLT2 inhibitors, like agents that block the renin-angiotensin system, reduce intraglomerular pressure and single nephron GFR, potentially affording renoprotection...
متن کامل